Dalcetrapib vs Obicetrapib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: CETP · full Atherosclerotic Cardiovascular Disease pipeline

Dalcetrapib

Developed by DalCor Pharmaceuticals under a licence from Roche

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Partial signal

NCT01516541 · Phase 3 · completed

The study was randomized and double-blind, compared dalcetrapib with placebo, and enrolled 2,220 participants. Its primary endpoint was a hard clinical composite cardiovascular outcome, but the comparison cannot be judged because trial results have not been posted.

Next expected readout: August 2027 · NCT05918861 (registry estimate)

Reported efficacy

Incidence of Cardiovascular Mortality and Morbidity (From date of randomization to first event up to 48 months): Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). (missed)

Result source: NCT00658515

Obicetrapib

Marketed by A. Menarini under a licence from NewAmsterdam Pharma

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Partial signal

NCT05142722 · Phase 3 · completed

Participants were randomized 2:1 to obicetrapib or placebo and the trial was quadruple-blinded, with 2,530 participants enrolled. The primary LDL-cholesterol endpoint was met, with a statistically significant treatment difference, but LDL cholesterol is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure, supporting a moderate grade.

Next expected readout: November 2026 · NCT06496243 (registry estimate)

Reported efficacy

Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571) (met)

Result source: NCT05142722

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDalcetrapibObicetrapib
LDL-C, % change—Not posted · NCT01516541-29.9% vs 2.7%−32.6 vs placebo10mg · wk 12 · n 1679NCT05142722
68 other results
  • -36.0% vs 0.3% 10 mg · wk 12 · n 232 · Phase 3 · primary NCT05425745
  • -45.6% vs 3.0% wk 12 · n 102 · Phase 3 · primary NCT06005597
  • -28.8% vs 3.0% wk 12 · n 102 · Phase 3 · primary NCT06005597
  • -45.6% vs -17.6% wk 12 · n 102 · Phase 3 · primary NCT06005597
  • -25.3% vs -1.3% 10mg · wk 52.142857142857146 · n 1679 · Phase 3 · secondary NCT05142722
  • -29.1% vs 4.7% 10mg · wk 25.714285714285715 · n 1685 · Phase 3 · secondary NCT05142722
  • -31.1% vs 10.3% 10 mg · wk 52 · n 232 · Phase 3 · secondary NCT05425745
  • -31.8% vs 6.0% 10 mg · wk 26 · n 234 · Phase 3 · secondary NCT05425745
  • -36.8% vs -0.8% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -45.8% vs -0.9% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -36.6% vs -0.5% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -36.3% vs 0.4% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -43.7% vs 0.7% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -36.1% vs 0.7% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -43.4% vs -5.5% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -45.6% vs 0% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -44.2% vs -5% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -46.1% vs -7.1% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -50.8% vs -6.5% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -46.8% vs -6.7% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -33.8% vs -0.8% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -31.9% vs -0.9% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -33.8% vs -0.5% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -30.5% vs 0.4% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -30.4% vs 0.7% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -30.5% vs 0.7% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -38.0% vs -5.5% 5 mg · wk 8 · n 39 · Phase 2 · primary NCT04753606
  • -42.9% vs 0% 5 mg · wk 8 · n 39 · Phase 2 · primary NCT04753606
  • -38.0% vs -5% 5 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -36.0% vs -7.1% 5 mg · wk 8 · n 38 · Phase 2 · primary NCT04753606
  • -41.5% vs -6.5% 5 mg · wk 8 · n 38 · Phase 2 · primary NCT04753606
  • -35.6% vs -6.7% 5 mg · wk 8 · n 38 · Phase 2 · primary NCT04753606
  • -25.9% vs -0.8% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -24.8% vs -0.9% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.3% vs -0.5% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.1% vs 0.4% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.0% vs 0.7% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.5% vs 0.7% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -59.1% vs -0.8% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -63.4% vs -6.3% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -59.2% vs -0.8% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -59.5% vs -1.5% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -62.8% vs -4.0% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -59.7% vs -1.5% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -45.6% vs -0.2% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -52.0% vs -1.4% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -43.5% vs 1.4% wk 8 · n 27 · Phase 2 · primary NCT04770389
  • -44.4% vs -1.5% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -51.4% vs -2% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -44.1% vs -0.8% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -39.4% vs -0.8% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -43.5% vs -6.3% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -39.2% vs -0.8% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -39.0% vs -1.5% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -43.5% vs -4.0% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -38.8% vs -1.5% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -31.9% vs -0.2% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -34.4% vs -1.4% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -32.0% vs 1.4% wk 8 · n 28 · Phase 2 · secondary NCT04770389
  • -27.9% vs -1.5% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -30.1% vs -2% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -29.0% vs -0.8% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -45.6% vs -12.7% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -52.0% vs -14.8% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -43.5% vs -13.4% wk 8 · n 27 · Phase 2 · secondary NCT04770389
  • -31.9% vs -12.7% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -34.4% vs -14.8% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -32.0% vs -13.4% wk 8 · n 28 · Phase 2 · secondary NCT04770389
Non-HDL-C, % change—Not posted · NCT01516541-22.4% vs 0.6%−23 vs placebo10mg · wk 52.142857142857146 · n 1685NCT05142722
23 other results
  • -24.6% vs 3.7% 10mg · wk 25.714285714285715 · n 1685 · Phase 3 · secondary NCT05142722
  • -26.6% vs 2.8% 10mg · wk 12 · n 1685 · Phase 3 · secondary NCT05142722
  • -25.8% vs 11.6% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT05425745
  • -27.1% vs 5.9% 10 mg · wk 26 · n 234 · Phase 3 · secondary NCT05425745
  • -31.6% vs 2.8% 10 mg · wk 12 · n 234 · Phase 3 · secondary NCT05425745
  • -42.4% vs 2.7% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -27.2% vs 2.7% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -42.4% vs -17.0% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -30.3% vs -1.8% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -37.0% vs -0.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -30.3% vs -1.7% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -39.3% vs -4.2% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -44.4% vs -3.5% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -39.9% vs -3.8% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -30.4% vs -1.8% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -29.8% vs -0.4% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -30.1% vs -1.7% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -34.3% vs -4.2% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -38.9% vs -3.5% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -34.4% vs -3.8% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -25.4% vs -1.8% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -23.7% vs -0.4% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -25.7% vs -1.7% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
ApoB, % change—Not posted · NCT01516541-15.6% vs -1.8%−13.8 vs placebo10mg · wk 52.142857142857146 · n 1685NCT05142722
38 other results
  • -16.1% vs 2.2% 10mg · wk 25.714285714285715 · n 1685 · Phase 3 · secondary NCT05142722
  • -17.8% vs 1.1% 10mg · wk 12 · n 1685 · Phase 3 · secondary NCT05142722
  • -17.6% vs 8.2% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT05425745
  • -18.3% vs 6.0% 10 mg · wk 26 · n 234 · Phase 3 · secondary NCT05425745
  • -21.4% vs 2.9% 10 mg · wk 12 · n 234 · Phase 3 · secondary NCT05425745
  • -26.9% vs 2.3% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -17.5% vs 2.3% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -26.9% vs -12.7% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -21.7% vs 0.5% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -24.2% vs -2.0% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -21.6% vs 0.7% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -26.7% vs -1.2% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -29.7% vs -0.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -26.3% vs -1.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -27.2% vs -4.7% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -29.8% vs -2.6% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -28.1% vs -4.1% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -24.5% vs -1.2% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -21.4% vs -0.4% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -23.9% vs -1.4% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -22.6% vs -4.7% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -24.4% vs -2.6% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -22.4% vs -4.1% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -19.8% vs -1.2% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -22.5% vs -0.4% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -20.4% vs -1.4% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -34.7% vs 0.5% wk 12 · n 31 · Phase 2 · secondary NCT05266586
  • -34.4% vs -2.0% wk 12 · n 31 · Phase 2 · secondary NCT05266586
  • -35.0% vs 0.7% wk 12 · n 31 · Phase 2 · secondary NCT05266586
  • -31.6% vs -1.2% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -34.8% vs -0.9% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -29.7% vs -0.1% wk 8 · n 27 · Phase 2 · secondary NCT04770389
  • -22.1% vs -1.2% wk 8 · n 26 · Phase 2 · secondary NCT04770389
  • -23.5% vs -0.9% wk 8 · n 26 · Phase 2 · secondary NCT04770389
  • -22.5% vs -0.1% wk 8 · n 28 · Phase 2 · secondary NCT04770389
  • -31.6% vs -8.8% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -34.8% vs -8.9% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -29.7% vs -8.9% wk 8 · n 27 · Phase 2 · secondary NCT04770389
Lp(a), % change—Not posted · NCT01516541-0.5% vs 13.7%−14.1 vs placebo10mg · wk 12 · n 1685NCT05142722
3 other results
  • -32.3% vs -0.9% 10mg · wk 12 · n 1685 · Phase 3 · secondary NCT05142722
  • -29.9% vs 24.4% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT05425745
  • -35.4% vs 10.5% 10 mg · wk 12 · n 234 · Phase 3 · secondary NCT05425745
3-point MACE (% with event)—Not posted · NCT01516541—Trial running · NCT05202509

LDL-C, % change

Dalcetrapib
—Not posted · NCT01516541
Obicetrapib
-29.9% vs 2.7%−32.6 vs placebo10mg · wk 12 · n 1679NCT05142722
68 other results
  • -36.0% vs 0.3% 10 mg · wk 12 · n 232 · Phase 3 · primary NCT05425745
  • -45.6% vs 3.0% wk 12 · n 102 · Phase 3 · primary NCT06005597
  • -28.8% vs 3.0% wk 12 · n 102 · Phase 3 · primary NCT06005597
  • -45.6% vs -17.6% wk 12 · n 102 · Phase 3 · primary NCT06005597
  • -25.3% vs -1.3% 10mg · wk 52.142857142857146 · n 1679 · Phase 3 · secondary NCT05142722
  • -29.1% vs 4.7% 10mg · wk 25.714285714285715 · n 1685 · Phase 3 · secondary NCT05142722
  • -31.1% vs 10.3% 10 mg · wk 52 · n 232 · Phase 3 · secondary NCT05425745
  • -31.8% vs 6.0% 10 mg · wk 26 · n 234 · Phase 3 · secondary NCT05425745
  • -36.8% vs -0.8% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -45.8% vs -0.9% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -36.6% vs -0.5% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -36.3% vs 0.4% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -43.7% vs 0.7% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -36.1% vs 0.7% 10 mg · wk 8 · n 26 · Phase 2 · primary NCT05421078
  • -43.4% vs -5.5% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -45.6% vs 0% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -44.2% vs -5% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -46.1% vs -7.1% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -50.8% vs -6.5% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -46.8% vs -6.7% 10 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -33.8% vs -0.8% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -31.9% vs -0.9% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -33.8% vs -0.5% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -30.5% vs 0.4% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -30.4% vs 0.7% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -30.5% vs 0.7% 5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -38.0% vs -5.5% 5 mg · wk 8 · n 39 · Phase 2 · primary NCT04753606
  • -42.9% vs 0% 5 mg · wk 8 · n 39 · Phase 2 · primary NCT04753606
  • -38.0% vs -5% 5 mg · wk 8 · n 40 · Phase 2 · primary NCT04753606
  • -36.0% vs -7.1% 5 mg · wk 8 · n 38 · Phase 2 · primary NCT04753606
  • -41.5% vs -6.5% 5 mg · wk 8 · n 38 · Phase 2 · primary NCT04753606
  • -35.6% vs -6.7% 5 mg · wk 8 · n 38 · Phase 2 · primary NCT04753606
  • -25.9% vs -0.8% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -24.8% vs -0.9% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.3% vs -0.5% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.1% vs 0.4% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.0% vs 0.7% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -26.5% vs 0.7% 2.5 mg · wk 8 · n 25 · Phase 2 · primary NCT05421078
  • -59.1% vs -0.8% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -63.4% vs -6.3% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -59.2% vs -0.8% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -59.5% vs -1.5% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -62.8% vs -4.0% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -59.7% vs -1.5% wk 12 · n 31 · Phase 2 · primary NCT05266586
  • -45.6% vs -0.2% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -52.0% vs -1.4% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -43.5% vs 1.4% wk 8 · n 27 · Phase 2 · primary NCT04770389
  • -44.4% vs -1.5% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -51.4% vs -2% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -44.1% vs -0.8% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -39.4% vs -0.8% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -43.5% vs -6.3% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -39.2% vs -0.8% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -39.0% vs -1.5% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -43.5% vs -4.0% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -38.8% vs -1.5% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -31.9% vs -0.2% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -34.4% vs -1.4% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -32.0% vs 1.4% wk 8 · n 28 · Phase 2 · secondary NCT04770389
  • -27.9% vs -1.5% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -30.1% vs -2% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -29.0% vs -0.8% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -45.6% vs -12.7% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -52.0% vs -14.8% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -43.5% vs -13.4% wk 8 · n 27 · Phase 2 · secondary NCT04770389
  • -31.9% vs -12.7% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -34.4% vs -14.8% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -32.0% vs -13.4% wk 8 · n 28 · Phase 2 · secondary NCT04770389

Non-HDL-C, % change

Dalcetrapib
—Not posted · NCT01516541
Obicetrapib
-22.4% vs 0.6%−23 vs placebo10mg · wk 52.142857142857146 · n 1685NCT05142722
23 other results
  • -24.6% vs 3.7% 10mg · wk 25.714285714285715 · n 1685 · Phase 3 · secondary NCT05142722
  • -26.6% vs 2.8% 10mg · wk 12 · n 1685 · Phase 3 · secondary NCT05142722
  • -25.8% vs 11.6% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT05425745
  • -27.1% vs 5.9% 10 mg · wk 26 · n 234 · Phase 3 · secondary NCT05425745
  • -31.6% vs 2.8% 10 mg · wk 12 · n 234 · Phase 3 · secondary NCT05425745
  • -42.4% vs 2.7% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -27.2% vs 2.7% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -42.4% vs -17.0% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -30.3% vs -1.8% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -37.0% vs -0.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -30.3% vs -1.7% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -39.3% vs -4.2% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -44.4% vs -3.5% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -39.9% vs -3.8% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -30.4% vs -1.8% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -29.8% vs -0.4% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -30.1% vs -1.7% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -34.3% vs -4.2% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -38.9% vs -3.5% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -34.4% vs -3.8% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -25.4% vs -1.8% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -23.7% vs -0.4% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -25.7% vs -1.7% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078

ApoB, % change

Dalcetrapib
—Not posted · NCT01516541
Obicetrapib
-15.6% vs -1.8%−13.8 vs placebo10mg · wk 52.142857142857146 · n 1685NCT05142722
38 other results
  • -16.1% vs 2.2% 10mg · wk 25.714285714285715 · n 1685 · Phase 3 · secondary NCT05142722
  • -17.8% vs 1.1% 10mg · wk 12 · n 1685 · Phase 3 · secondary NCT05142722
  • -17.6% vs 8.2% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT05425745
  • -18.3% vs 6.0% 10 mg · wk 26 · n 234 · Phase 3 · secondary NCT05425745
  • -21.4% vs 2.9% 10 mg · wk 12 · n 234 · Phase 3 · secondary NCT05425745
  • -26.9% vs 2.3% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -17.5% vs 2.3% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -26.9% vs -12.7% wk 12 · n 102 · Phase 3 · secondary NCT06005597
  • -21.7% vs 0.5% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -24.2% vs -2.0% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -21.6% vs 0.7% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT05266586
  • -26.7% vs -1.2% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -29.7% vs -0.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -26.3% vs -1.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT05421078
  • -27.2% vs -4.7% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -29.8% vs -2.6% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -28.1% vs -4.1% 10 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -24.5% vs -1.2% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -21.4% vs -0.4% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -23.9% vs -1.4% 5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -22.6% vs -4.7% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -24.4% vs -2.6% 5 mg · wk 8 · n 39 · Phase 2 · secondary NCT04753606
  • -22.4% vs -4.1% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT04753606
  • -19.8% vs -1.2% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -22.5% vs -0.4% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -20.4% vs -1.4% 2.5 mg · wk 8 · n 25 · Phase 2 · secondary NCT05421078
  • -34.7% vs 0.5% wk 12 · n 31 · Phase 2 · secondary NCT05266586
  • -34.4% vs -2.0% wk 12 · n 31 · Phase 2 · secondary NCT05266586
  • -35.0% vs 0.7% wk 12 · n 31 · Phase 2 · secondary NCT05266586
  • -31.6% vs -1.2% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -34.8% vs -0.9% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -29.7% vs -0.1% wk 8 · n 27 · Phase 2 · secondary NCT04770389
  • -22.1% vs -1.2% wk 8 · n 26 · Phase 2 · secondary NCT04770389
  • -23.5% vs -0.9% wk 8 · n 26 · Phase 2 · secondary NCT04770389
  • -22.5% vs -0.1% wk 8 · n 28 · Phase 2 · secondary NCT04770389
  • -31.6% vs -8.8% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -34.8% vs -8.9% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -29.7% vs -8.9% wk 8 · n 27 · Phase 2 · secondary NCT04770389

Lp(a), % change

Dalcetrapib
—Not posted · NCT01516541
Obicetrapib
-0.5% vs 13.7%−14.1 vs placebo10mg · wk 12 · n 1685NCT05142722
3 other results
  • -32.3% vs -0.9% 10mg · wk 12 · n 1685 · Phase 3 · secondary NCT05142722
  • -29.9% vs 24.4% 10 mg · wk 52 · n 234 · Phase 3 · secondary NCT05425745
  • -35.4% vs 10.5% 10 mg · wk 12 · n 234 · Phase 3 · secondary NCT05425745

3-point MACE (% with event)

Dalcetrapib
—Not posted · NCT01516541
Obicetrapib
—Trial running · NCT05202509
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Dalcetrapib: 4 of 5 rows · Obicetrapib: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDalcetrapibObicetrapib
HDL-C
percent change · % of baseline
13.92% (n=72) vs 0.73% (n=73) placebo @ 12wk900mga,b,c,d
NCT00697203 · Phase 2 · registry result, not featured evidence
show 2 more doses
11.9% (n=67) vs 0.73% (n=73) placebo @ 12wk600mg
NCT00697203 · Phase 2 · registry result, not featured evidence
6.58% (n=75) vs 0.73% (n=73) placebo @ 12wk300mg
NCT00697203 · Phase 2 · registry result, not featured evidence
136.87% (n=1685) vs 0.61% (n=843) placebo @ 12wk10mgb,c,d
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
1 other source trial
139.92% (n=234) vs 1.26% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Dropout rate
2.1%e
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 4 more results
17.2%
NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2
10.8%900mg
NCT00697203 · Phase 2 · registry result, not featured evidence
8.8%600mg
NCT00697203 · Phase 2 · registry result, not featured evidence
11.8%300mg
NCT00697203 · Phase 2 · registry result, not featured evidence
5.1%10mgf
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 12 more results
4.2%10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2%Fixed Dose Combination
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
2.9%Monotherapy Obicetrapib
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0%10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
0%2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
7.7%10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
5%Combination Therapy
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
0%10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
18.5%Combination Therapy
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
7.1%Obicetrapib Monotherapy
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
Discontinued due to AEs
—e
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 4 more results
—
NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2
—900mg
NCT00697203 · Phase 2 · registry result, not featured evidence
—600mg
NCT00697203 · Phase 2 · registry result, not featured evidence
—300mg
NCT00697203 · Phase 2 · registry result, not featured evidence
0.1%10mgf
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 12 more results
0.4%10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Fixed Dose Combination
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
—Monotherapy Obicetrapib
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
—5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
5.1%10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
2.5%Combination Therapy
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
0%10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
7.4%Combination Therapy
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
0%Obicetrapib Monotherapy
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
Serious AEs
12.9%e
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 4 more results
31.3%
NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2
4.1%900mg
NCT00697203 · Phase 2 · registry result, not featured evidence
2.9%600mg
NCT00697203 · Phase 2 · registry result, not featured evidence
2.6%300mg
NCT00697203 · Phase 2 · registry result, not featured evidence
12.5%10mgf
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 12 more results
5.6%10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.9%Fixed Dose Combination
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
5.9%Monotherapy Obicetrapib
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0%10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
4%5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
0%2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
2.6%10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
0%Combination Therapy
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
0%10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
0%Combination Therapy
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
0%Obicetrapib Monotherapy
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
Most frequent reported AEs
e
chest pain 10.1% (placebo 7.8%)
diarrhea 8.6% (placebo 5.8%)
hypertension 8% (placebo 4.1%)
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
10mgf
hypertension 4.9% (placebo 3.9%)
covid-19 4.8% (placebo 5.7%)
upper respiratory tract infection 2.9% (placebo 3.9%)
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 12 more results
10 mg
influenza 9% (placebo 5.9%)
covid-19 6.4% (placebo 6.8%)
nasopharyngitis 6.4% (placebo 4.2%)
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
diarrhoea 4.9% (placebo 0%)
covid-19 3.9% (placebo 1%)
fatigue 3.9% (placebo 1%)
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
hypertension 8.8% (placebo 2.9%)
arthralgia 6.9% (placebo 2.9%)
headache 5.9% (placebo 2%)
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
10 mg
back pain 7.7% (placebo 11.5%)
nasopharyngitis 7.7% (placebo 11.5%)
rhinitis allergic 7.7% (placebo 0%)
NCT05421078 · Phase 2 · registry result, not featured evidence
5 mg
blood glucose increased 4% (placebo 0%)
blood pressure increased 4% (placebo 0%)
chest pain 4% (placebo 0%)
NCT05421078 · Phase 2 · registry result, not featured evidence
2.5 mg
diabetes mellitus 8% (placebo 0%)
hypoglycaemia 8% (placebo 0%)
abdominal distension 4% (placebo 0%)
NCT05421078 · Phase 2 · registry result, not featured evidence
10 mg
abdominal pain 2.6% (placebo 0%)
abdominal pain upper 2.6% (placebo 0%)
acute myocardial infarction 2.6% (placebo 0%)
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
nausea 5% (placebo 5%)
arthralgia 2.5% (placebo 2.5%)
bronchitis 2.5% (placebo 0%)
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
10 mg
arthralgia 2.5% (placebo 2.5%)
arthropod sting 2.5% (placebo 0%)
cardiomegaly 2.5% (placebo 0%)
NCT04753606 · Phase 2 · registry result, not featured evidence
5 mg
fatigue 5% (placebo 5%)
hypertension 5% (placebo 0%)
type 2 diabetes mellitus 5% (placebo 0%)
NCT04753606 · Phase 2 · registry result, not featured evidence
diarrhoea 7.4% (placebo 0%)
abdominal pain 3.7% (placebo 0%)
back pain 3.7% (placebo 0%)
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
covid-19 3.6% (placebo 0%)
flatulence 3.6% (placebo 0%)
onychomycosis 3.6% (placebo 0%)
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation comparability has not been reviewed for 3 of these studies.
  6. fPopulation comparability has not been reviewed for 9 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dalcetrapib

PAV 0.6% (n=474) vs 0.5% (n=462) placebo @ 104wk
percent change · % of baseline
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
CIMT Change Rate MM Per 0.003 vs 0.003 placebo per year @ 104wk
absolute change · per year
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Minimal Lumen Diameter Change -0.1 vs 0 placebo mm @ 104wk
absolute change · mm
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Percent Diameter Stenosis 9.2% (n=474) vs 4.3% (n=462) placebo @ 104wk
absolute change · percentage points
NCT01059682 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Wall Thickness 4.245% (n=64) vs 6.679% (n=66) placebo @ 104wk
percent change · % of baseline
NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2
Plaque Target to Background -0.188 vs -0.26 placebo ratio @ 26wk
ratio to baseline · ratio
NCT00655473 · Phase 2 · Atherosclerotic Cardiovascular Disease · phase 2
HDL-C Change mg/dL 36.45 vs 2.31 placebo mg/dL @ 12wk900mg
absolute change · mg/dL
NCT00697203 · Phase 2 · registry result, not featured evidence
show 2 more results
31.42 vs 2.31 placebo mg/dL @ 12wk600mg
NCT00697203 · Phase 2 · registry result, not featured evidence
17.18 vs 2.31 placebo mg/dL @ 12wk300mg
NCT00697203 · Phase 2 · registry result, not featured evidence

Obicetrapib

LDL-C -29.94% (n=1679) vs 2.7% (n=842) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 68 more results
-29.09% (n=1685) vs 4.68% (n=843) placebo @ 25.714285714285715wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-25.25% (n=1679) vs -1.27% (n=842) placebo @ 52.142857142857146wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-36.05% (n=232) vs 0.25% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-31.8% (n=234) vs 5.98% (n=118) placebo @ 26wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-31.14% (n=232) vs 10.3% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-36.8% (n=26) vs -0.78% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-45.8% (n=26) vs -0.89% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-36.6% (n=26) vs -0.48% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-36.29% (n=26) vs 0.43% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-43.72% (n=26) vs 0.67% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-36.12% (n=26) vs 0.69% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-39.35% (n=26) vs -0.83% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-43.5% (n=26) vs -6.35% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-39.2% (n=26) vs -0.85% (n=40) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-39.04% (n=26) vs -1.49% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-43.55% (n=26) vs -3.95% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-38.75% (n=26) vs -1.54% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-43.35% (n=40) vs -5.48% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-45.65% (n=40) vs 0% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-44.18% (n=40) vs -5% (n=40) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-46.06% (n=40) vs -7.11% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-50.75% (n=40) vs -6.5% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-46.77% (n=40) vs -6.7% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-33.78% (n=25) vs -0.78% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-31.94% (n=25) vs -0.89% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-33.82% (n=25) vs -0.48% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-30.5% (n=25) vs 0.43% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-30.4% (n=25) vs 0.67% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-30.54% (n=25) vs 0.69% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-37.97% (n=39) vs -5.48% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-42.9% (n=39) vs 0% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-37.97% (n=40) vs -5% (n=40) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-35.98% (n=38) vs -7.11% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-41.45% (n=38) vs -6.5% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-35.65% (n=38) vs -6.7% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-25.9% (n=25) vs -0.78% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-24.81% (n=25) vs -0.89% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-26.32% (n=25) vs -0.48% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-26.1% (n=25) vs 0.43% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-25.97% (n=25) vs 0.67% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-26.51% (n=25) vs 0.69% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-45.58% (n=102) vs 3.03% (n=100) placebo @ 12wk
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-45.58% (n=102) vs -17.63% (n=101) Ezetimibe @ 12wk
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-28.82% (n=102) vs 3.03% (n=100) placebo @ 12wk
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-59.07% (n=31) vs -0.83% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-63.4% (n=31) vs -6.35% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-59.23% (n=31) vs -0.85% (n=40) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-59.51% (n=31) vs -1.49% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-62.8% (n=31) vs -3.95% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-59.69% (n=31) vs -1.54% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-45.63% (n=24) vs -0.17% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-51.95% (n=24) vs -1.4% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-43.55% (n=27) vs 1.37% (n=28) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-44.38% (n=24) vs -1.53% (n=22) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-51.4% (n=24) vs -2% (n=22) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-44.1% (n=24) vs -0.78% (n=22) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-31.88% (n=25) vs -0.17% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-34.4% (n=25) vs -1.4% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-31.99% (n=28) vs 1.37% (n=28) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-27.94% (n=25) vs -1.53% (n=22) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-30.1% (n=25) vs -2% (n=22) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-28.98% (n=25) vs -0.78% (n=22) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-45.63% (n=24) vs -12.69% (n=25) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-51.95% (n=24) vs -14.8% (n=25) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-43.55% (n=27) vs -13.42% (n=28) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-31.88% (n=25) vs -12.69% (n=25) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-34.4% (n=25) vs -14.8% (n=25) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-31.99% (n=28) vs -13.42% (n=28) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
Apo B -17.84% (n=1685) vs 1.08% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 38 more results
-16.07% (n=1685) vs 2.23% (n=843) placebo @ 25.714285714285715wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-15.57% (n=1685) vs -1.77% (n=843) placebo @ 52.142857142857146wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-21.45% (n=234) vs 2.93% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-18.3% (n=234) vs 6.02% (n=118) placebo @ 26wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-17.62% (n=234) vs 8.15% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-26.66% (n=26) vs -1.23% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-29.67% (n=26) vs -0.36% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-26.29% (n=26) vs -1.42% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-21.73% (n=26) vs 0.51% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-24.2% (n=26) vs -2.05% (n=36) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-21.56% (n=26) vs 0.72% (n=40) placebo @ 12wk10 mg
NCT05266586 · Phase 2 · registry result, not featured evidence · monotherapy
-27.19% (n=40) vs -4.67% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-29.75% (n=40) vs -2.6% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-28.12% (n=40) vs -4.13% (n=40) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-24.48% (n=25) vs -1.23% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-21.43% (n=25) vs -0.36% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-23.87% (n=25) vs -1.42% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-22.62% (n=39) vs -4.67% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-24.4% (n=39) vs -2.6% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-22.4% (n=40) vs -4.13% (n=40) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-19.8% (n=25) vs -1.23% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-22.5% (n=25) vs -0.36% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-20.43% (n=25) vs -1.42% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-26.91% (n=102) vs 2.28% (n=102) placebo @ 12wk
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-17.5% (n=102) vs 2.28% (n=102) placebo @ 12wk
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-26.91% (n=102) vs -12.71% (n=101) Ezetimibe @ 12wk
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-34.66% (n=31) vs 0.51% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-34.4% (n=31) vs -2.05% (n=36) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-34.95% (n=31) vs 0.72% (n=40) placebo @ 12wk
NCT05266586 · Phase 2 · registry result, not featured evidence · combination
-31.62% (n=24) vs -1.17% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-34.75% (n=24) vs -0.9% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-29.73% (n=27) vs -0.11% (n=28) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-22.15% (n=26) vs -1.17% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-23.5% (n=26) vs -0.9% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-22.46% (n=28) vs -0.11% (n=28) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
-31.62% (n=24) vs -8.78% (n=25) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-34.75% (n=24) vs -8.9% (n=25) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-29.73% (n=27) vs -8.92% (n=28) Ezetimibe @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
Non-HDL-C -26.64% (n=1685) vs 2.81% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 23 more results
-24.63% (n=1685) vs 3.68% (n=843) placebo @ 25.714285714285715wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-22.38% (n=1685) vs 0.63% (n=843) placebo @ 52.142857142857146wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-31.62% (n=234) vs 2.83% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-27.08% (n=234) vs 5.92% (n=118) placebo @ 26wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-25.84% (n=234) vs 11.64% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-30.25% (n=26) vs -1.8% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-36.96% (n=26) vs -0.37% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-30.28% (n=26) vs -1.72% (n=26) placebo @ 8wk10 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-39.25% (n=40) vs -4.22% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-44.4% (n=40) vs -3.5% (n=39) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-39.86% (n=40) vs -3.83% (n=40) placebo @ 8wk10 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-30.38% (n=25) vs -1.8% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-29.82% (n=25) vs -0.37% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-30.11% (n=25) vs -1.72% (n=26) placebo @ 8wk5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-34.28% (n=39) vs -4.22% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-38.9% (n=39) vs -3.5% (n=39) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-34.37% (n=40) vs -3.83% (n=40) placebo @ 8wk5 mg
NCT04753606 · Phase 2 · registry result, not featured evidence
-25.42% (n=25) vs -1.8% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-23.74% (n=25) vs -0.37% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-25.66% (n=25) vs -1.72% (n=26) placebo @ 8wk2.5 mg
NCT05421078 · Phase 2 · registry result, not featured evidence
-42.42% (n=102) vs 2.71% (n=102) placebo @ 12wk
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-27.19% (n=102) vs 2.71% (n=102) placebo @ 12wk
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-42.42% (n=102) vs -16.98% (n=101) Ezetimibe @ 12wk
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
Lp(a -0.48% (n=1685) vs 13.65% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 3 more results
-32.3% (n=1685) vs -0.9% (n=843) placebo @ 12wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-35.42% (n=234) vs 10.52% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-29.93% (n=234) vs 24.37% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Apo A1 43.44% (n=1685) vs 0.26% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Total Cholesterol 17.66% (n=1685) vs -0.02% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
18.68% (n=1685) vs 0.85% (n=843) placebo @ 25.714285714285715wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
17.96% (n=1685) vs -0.58% (n=843) placebo @ 52.142857142857146wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
12.09% (n=234) vs 2.34% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
14.43% (n=234) vs 4.44% (n=118) placebo @ 26wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
13.92% (n=234) vs 9.32% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Triglycerides -0.17% (n=1685) vs 7.66% (n=843) placebo @ 12wk10mg
percent change · % of baseline
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
0.25% (n=1685) vs 8.22% (n=843) placebo @ 25.714285714285715wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0.6% (n=1685) vs 6.33% (n=843) placebo @ 52.142857142857146wk10mg
NCT05142722 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-1.57% (n=234) vs 10.16% (n=118) placebo @ 12wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
4.49% (n=234) vs 12.43% (n=118) placebo @ 26wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.27% (n=234) vs 7.39% (n=118) placebo @ 52wk10 mg
NCT05425745 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C -45.58% (n=102) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
-28.82% (n=102) @ 12wk
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Non-HDL-C -42.42% (n=102) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
-27.19% (n=102) @ 12wk
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Apo B -26.91% (n=102) @ 12wk
percent change · % of baseline
No placebo or comparator arm
NCT06005597 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more result
-17.5% (n=102) @ 12wk
NCT06005597 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dalcetrapib's landscape · Obicetrapib's landscape